Company Announcements

Director/PDMR Shareholding

Source: RNS
RNS Number : 9387Z
Yourgene Health PLC
24 September 2020
 

 

Yourgene Health plc

("Yourgene" or the "Company")

 

Director/PDMR Shareholding

 

Manchester, UK - 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it was notified today of the following directors' share purchases.

 

The following directors have made the following share purchases on 23 September 2020:

 

Director

Purchase price

Number of shares purchased

Total number of shares owned following purchase

Percentage of issued share capital held following purchase

Adam Reynolds

17 pence

294,117

6,743,773

0.92%

Lyn Rees

17 pence

294,000

1,037,902

0.14%

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

investors@yourgene-health.com

Barry Hextall, Chief Financial Officer

 

Joanne Cross, Director of Marketing

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: +44 (0)20 7213 0880

Liam Murray / James Caithie / Ludovico Lazzaretti




N+1 Singer (Joint Corporate Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas

 

 

 

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Tel: +44 (0)20 7710 7600

Nicholas Moore / Matthew Blawat / Ben Maddison

 

 

 

 

 

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

 Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / Mob: 07584 391 303  

 

 

 

  

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

 

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

 

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.

 

Yourgene is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Adam Reynolds

b) Lyn Rees

 

2

Reason for notification

  

a.

Position/Status

a) Non-executive Chairman

b) Chief Executive Officer

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Yourgene Health plc

b.

LEI

213800UUIT8BZE7QEH33

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 0.1p each

 

ISIN: GB00BN31ZD89

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)







Price(s)

Volume(s)


a) 17p

b) 17p

a) 294,117

b) 294,000


 

 

e.

Date of the transaction

23 September 2020

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKXLFLBKLEBBE